Table 1 Selected examples of differential phosphorylation stoichiometry between drug sensitive (PC9) and resistance (PC9/gef.) lung cancer cell.
Protein | p-site | p-site ratio | Motif | Stoichiometry | Protein ratio | ||
|---|---|---|---|---|---|---|---|
PC9 | PC9/gef. | Difference | |||||
HMGA1 | T53 | ND | CK2 | 6% | 42% | 36% | 0.3 |
AP2A1 | Y418 | ND | EGFR | 11% | 34% | 23% | 1.4 |
CDK1 | S39 | ND | CK2 | 1% | 33% | 32% | 0.7 |
DKC1 | S453 | 2.4 | CK2 | 45% | 77% | 32% | 2.4 |
PTPN3 | S425 | 2.4 | CK2 | 27% | 56% | 29% | 1.4 |
KPNA3 | S60 | 2.5 | CK2 | 34% | 58% | 24% | 3.4 |
CEBPB | T235 | 2.3 | MAPK | 41% | 62% | 21% | 1.7 |
HNRNPK | Y280 | ND | EGFR | 0% | 20% | 20% | 0.9 |
MET | T977 | ND | MAPK | 0% | 14% | 14% | 1.7 |
SF3A1 | S359 | 3.5 | CK2 | 100% | 100% | 0% | 2 |
NOP56 | S520 | 5.1 | CK2 | 63% | 61% | −2% | 2.1 |
EGFR | Y1197 | ND | EGFR | 34% | 22% | −12% | 0.8 |
HDAC2 | S394 | 0.1 | CK2 | 100% | 86% | −14% | 1.7 |
